TS Picks: April 29, 2015

Journal explains embryo-editing publication; genetic-testing firms enter drug development; questioning a “disruptive” technology

Tracy Vence
Apr 29, 2015

WIKIMEDIA, RWJMS IVF PROGRAM

Selections from The Scientist’s reading list:
 

  • In an April 28 editorial, Protein & Cell explained its decision to publish a controversial paper in which researchers reported editing a gene in early human embryos. “Protein & Cell has fully realized that this study can provide direct evidences to address some of the safety concerns of the CRISPR/Cas9 technique,” wrote Xiaoxue Zhang, the journal’s managing editor. “Until a consensus on new regulatory rules can be reached, it is in the best interest of all parties that the research field should voluntarily avoid any study that may pose potential safety and/or ethical risks.” (Hat tip: ScienceInsider)
     
  • As genetic-testing companies such as 23andMe dive into drug development and social networking-based platforms like “Genes for Good” aim to gather large quantities of genetic data, it’s clear that commercial interest in this information is growing,...